Life Sciences Gene Editing Platforms sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Gene Editing Platforms
1.1 - About Life Sciences Gene Editing Platforms sector
Companies in Life Sciences Gene Editing Platforms build software, reagents, and delivery technologies that enable precise genome modification for research and therapeutic development. Their offerings support CRISPR guide design, editing execution, and validation across cell lines and model organisms. Buyers rely on these vendors to increase editing accuracy, streamline workflows, and generate reproducible data that advances discovery programs and accelerates preclinical and clinical milestones.
Typical capabilities include CRISPR design and analytics software that optimizes guide selection, libraries of gRNAs and nucleases spanning Cas9, base and prime editors, and delivery systems such as AAV, lentiviral vectors, and lipid nanoparticles. Vendors provide off‑target detection and NGS pipelines, QC/validation assays, and cell line and model engineering services, with GMP‑grade materials, automation integrations, and compliance tooling for translational and clinical workflows.
They primarily serve cell and gene therapy developers, biopharma discovery teams, and academic core labs/CROs. Outcomes include faster target validation and edit optimization, higher on‑target efficiency with reduced off‑target risk, scalable preclinical testing, and audit‑ready documentation that supports regulatory submissions. By standardizing design-to-validation workflows, these platforms shorten program timelines and de‑risk movement from exploratory research into IND‑enabling studies.
2. Buyers in the Life Sciences Gene Editing Platforms sector
2.1 Top strategic acquirers of Life Sciences Gene Editing Platforms companies
eGenesis
HQ: United States
Website
- Description: Provider of multiplexed gene-editing xenotransplantation solutions that develop human-compatible organs, tissues and cells—such as genetically engineered pig kidneys and livers—to offer a scalable alternative to allotransplantation and address the global organ shortage.
- Key Products:
- Multiplexed Gene Editing Platform: Proprietary multiplex genome-engineering system edits multiple porcine genes simultaneously to eliminate immunogenic markers and viruses, producing organs, tissues and cells compatible with humans for clinical transplantation
- EGEN-5784 Genetically Engineered Porcine Liver: Human-compatible pig liver engineered via CRISPR and used with OrganOx extracorporeal liver cross-circulation system to support acute-on-chronic liver failure patients in Phase 1 safety and performance trials
- Genetically Engineered Pig Kidneys: CRISPR-edited porcine kidneys with removed PERVs and key immunogenic epitopes, currently in FDA-authorized expanded-access study to treat end-stage kidney disease and reduce dialysis dependence
- Pipeline of Human-Compatible Organs: Ongoing liver, kidney and heart programs using multiplex editing and novel immune-suppression regimens to create commercially viable xenotransplant organs that overcome historical virology and immunology barriers.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Life Sciences Gene Editing Platforms sector
M&A buyer group 1: Synthetic Biology Platforms
6 companies
View group →
Description: Companies in the Life Sciences Synthetic Biology Platform Software category provide computational and automation systems that power design–build–test–learn workflows for engineered cells and microbes. Their platforms unify sequence design, experiment orchestration, lab data capture, and analytics to streamline strain optimization and pathway engineering. By integrating biofoundry automation and cloud data infrastructure, they help customers accelerate R&D, standardize protocols, and move candidates from bench to pilot scale more predictably.
Amyris
- Type: N/A
- Employees: ●●●●●
- Description: Provider of consumer products and science-based ingredients, offering health and wellness, clean beauty, personal care, and flavor and fragrance ingredients that are sold through e-commerce, retail channels and directly to formulators, distributors and joint-venture partners.
- Key Products:
- Zero Calorie Sugarcane-Derived Sweetener: Fermented from sugarcane to 95 % purity, delivering a zero-calorie sweet taste without bitter aftertaste and produced sustainably at scale
- Bioscience Fermentation Platform: Proprietary microbial engineering process converting plant sugars into hydrocarbon molecules, enabling large-scale production of renewable specialty ingredients for multiple consumer markets
- No Compromise Ingredient Portfolio: Range of sustainable health, beauty, flavor and fragrance molecules supplied to brand partners, offering high performance with reduced environmental impact.
🔒
🔒
🔒
View all 6 companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms in Life Sciences Gene Editing Platforms sector
3.1 - Buyout funds in the Life Sciences Gene Editing Platforms sector
2.2 - Strategic buyer groups for Life Sciences Gene Editing Platforms sector
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Life Sciences Gene Editing Platforms companies
4.2 - Public trading comparable groups for Life Sciences Gene Editing Platforms sector
Valuation benchmark group 1: Biologic Drug Discovery Tools Companies
3 companies
View group →
Description: Companies in this trading comparable group are public providers of biologics-focused discovery tools and platforms. They supply recombinant proteins, antibodies, assay reagents, and custom production plus AI-enabled design services that accelerate preclinical research and therapeutic development. They are grouped as comparables given shared catalog and services revenue models, overlapping pharma and research customers, and biotech tools margin profiles, offering consistent public trading comparables for valuation.
Vazyme Biotech
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of biotechnology solutions specializing in the design, manufacture, and application of bioactive proteins and compounds. The company focuses on innovative enzyme-based solutions for clinical and molecular diagnostics, among other applications.
- Key Products:
- COVID-19 Solution: Comprehensive assay and diagnostic solutions for COVID-19 testing, including qPCR kits and antibodies
- Molecular Biology Solutions: Offering reagents for PCR, qPCR, and NGS applications, catering to research and diagnostic needs
- Custom Oligos: Providing custom oligonucleotide synthesis services with a focus on high-performance and precision
- Enzyme Technologies: Development and manufacturing of enzyme solutions for diverse biological applications
- Reagent Kits: Producing high-quality reagent kits for DNA and RNA extraction and sequencing.
🔒
🔒
🔒
View all 3 companies in this group
Request Free Trial Now →
🔒
Revenue growth
Median
15.7%
2025E
16.0%
2026E
EBITDA margin
Median
28.2%
2025E
28.6%
2026E
Cash EBITDA margin
Median
27.6%
2025E
28.0%
2026E
EV/Revenue
Median
8.4x
2025E
6.8x
2026E
EV/EBITDA
Median
28.9x
2025E
24.4x
2026E
EV/Cash EBITDA
Median
29.0x
2025E
25.5x
2026E
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →